Summit Therapeutics Inc. (SMMT) stock: price, suppliers, customers and institutional ownership
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae infections; and DDS-04 series for the potential treatment of infections caused by the Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.
4 readings, 2 filed under bull and 2 under bear. Every figure is ours; the model chose the side.
the bull case· 2
23
managers forming the concentrated core of reported holdings
13fJun 30 '26+2.41%
largest reporting managers increasing combined shares over the latest quarter
13fJun 30 '26the bear case· 2
9 of 20
largest reporting managers that trimmed their position in the latest quarter
13fJun 30 '26244
managers reporting a position in institutional filings
13fJun 30 '26The model filed each reading under bull or bear and wrote its caption; a caption carrying a digit is replaced by our own phrase, so every figure on this zone is ours. Built Sep 16 '26 against the Nov 3 '26 report; rebuilt when that date rolls. Not a forecast, not advice.
tall tick = annual report · 1 on record
244 managers report a position worth $2.1B between them, and 23 of them hold 80% of it.
Summit Therapeutics Inc. has no measured co-movers clearing our correlation floor, so only its SEC classification is shown.
SIC 2834, Pharmaceutical Preparations, from each company's own filings. Largest first.
Prev close 17.41 · gapped below the open, then crossed back over prior close. High/low 17.68 at 11:00 am ET, 17.15 at 9:45 am ET.
Summit Therapeutics Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Pharmaceutical Preparations
SMMT (Summit Therapeutics Inc.) has 6 disclosed suppliers and 2 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.
Largest move on the map today: JPM −0.24%, in financials.